A new study finds four factors that may make it more likely for some people to experience successful weight loss from using ...

Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

When researchers analyzed weight loss results from patients who took GLP-1 drugs and those who'd undergone bariatric surgery, ...

In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...